Ashling Holland

Company: PepGen

Job title: Director - Research & Preclinical Development

Seminars:

Enhanced Delivery Oligonucleotide (EDO) – A Novel Peptide Delivery Platform for Superior Oligonucleotide Delivery 11:30 am

EDOs are designed to enhance delivery of oligonucleotide therapeutics to muscle and other target tissues EDOs show higher uptake to muscle nuclei and corresponds with increased pharmacological activity in multiple preclinical models EDO platform has enabled initiation of 2 clinical programs, including a Phase 2 (CONNECT1-EDO51) study to investigate the effects of PGN-EDO51 in people…Read more

day: Conference Day Two